Equibles does not estimate personal net worth.
Get an email with a short summary when Collegium Pharmaceutical, Inc publishes a filing, an earnings call transcript or a press release.
Get COLL alertsColleen Tupper is recorded as CFO at Collegium Pharmaceutical, Inc (COLL). The proxy statement of Collegium Pharmaceutical, Inc reports total compensation of $3,515,055 for Colleen Tupper in fiscal 2025, including a base salary of $559,340. Disclosed compensation is on record for 6 fiscal years. Colleen Tupper has spoken on 20 earnings calls and 4 other investor events across 1 company, most recently for Collegium Pharmaceutical, Inc on September 15, 2026. Collegium Pharmaceutical, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Collegium Pharmaceutical, Inc includes Gino Santini (Chairman and Board Member), David Dieter (General Counsel), Shirley Kuhlmann (General Counsel) and 7 others.
“So, Extansa had revenues of about $200 million in 2025 and maintains its exclusivity until September of 2033. Prescription volumes have been down across all long-acting branded opioids this year.”
“In the second quarter, we again saw significant growth in Jornay, along with initial revenue from Astaris and meaningful revenues from our pain portfolio. Financial highlights for the second quarter include total net product revenues were $199.9 million in the quarter, up 6% year-over-year.”
“So high level, to just repeat, overall, we expect a longer and more robust tail for our pain portfolio. Nucenta specifically, as Vikram mentioned, has had generic activity already this year.”
“We are encouraged by our first quarter results, which reflect significant Jornay PM growth, consistent paying portfolio performance, and robust cash generation.”
“So, Collegium is acquiring Astaris and all related IP and global rights from Corium, which is a private company. We are paying $650 million up front. We are gaining an asset that is unencumbered by any royalties.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | $559,340 | $3,515,055 |
| 2024 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | $514,708 | $3,189,972 |
| 2023 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | $485,574 | $2,734,857 |
| 2022 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | $458,089 | $2,318,904 |
| 2021 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | $259,327 | $2,299,575 |
| 2020 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Financial Officer | — | — |
